Brought to you by 
Sosei acquires UK biotech Heptares for $180mm in cash, plus earn-outs
20 Sep 2017
Executive Summary
Sosei Group Corp. acquired private UK biotech Heptares Therapeutics Ltd. (structure-based drug design). Heptares will become a wholly owned subsidiary of Sosei and continue its existing R&D operations in the UK under the management of current Heptares CEO Malcolm Weir, PhD (who will also head worldwide R&D outside Japan).
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Sosei acquires UK biotech Heptares for $180mm in cash, plus earn-outs
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice